The development and implementation of polygenic risk scoring algorithms for stratifying individuals for future cognitive decline due to Alzheimer's Disease in non-symptomatic and early cognitive impaired subjects

This project will evaluate the utility of genetic based risk stratification for future cognitive decline in cognitively normal subjects and those with Mild Cognitive Impairment (MCI). MCI may be a prodromal state for AD (Alzheimer's Disease) and 50-60% of these patients are at high risk of progression to AD, however current prognostic methods for AD are only 25-30% accurate in early MCI. The lack of validated biomarkers hampers clinical management of these patients and also the development of new therapies useful in Alzheimer's Disease. This project will study large cohorts of patients and cognitively normal subjects to demonstrate the validity of a panel of identified at-risk AD biomarkers. Such a prognostic test is essential to enable meaningful clinical trials of emergent AD therapies.